

Duchenne Muscular Dystrophy Agents
Vyondys 53 (golodirsen)
Effective 06/01/2025

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Contact Information	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Notes	Vyondys 53 is also available on the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria. Additional agents from this class are available through the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria.		

Overview

Vyondys 53 (golodirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Diagnosis of Duchenne Muscular Dystrophy
2. Documentation of a confirmed out of frame deletion in the DMD that is amenable to exon 53 skipping
3. The prescribing physician is a neuromuscular neurologist or consult notes from a neuromuscular neurology office are provided
4. The member is ambulatory as defined by a current six-minute walk test (6MWT - distance walked in six minutes in meters) of ≥ 200 meters (test must have been observed or completed by the treating provider, or ordered by the treating provider and completed by a qualified medical practitioner)
5. Dosing is appropriate (30 mg/kg intravenously every week)
6. Member has received a corticosteroids for at least 6 months prior and member will continue to use a corticosteroid in combination with the requested agent **OR** a demonstrated contraindication to corticosteroids

7. Member has at least a baseline measurement for ALL of the following timed function tests as shown in medical records (tests must have been observed or completed by the treating provider, or ordered by the treating provider and completed by a qualified medical practitioner):
 - a. Timed ten-meter walk/run (time in seconds)
 - b. Timed floor (supine) to stand (time in seconds)
 - c. Timed four-step descend (time in seconds)
 - d. Timed four-step climb (time in seconds)
 - e. Timed sit to stand (time in seconds)

Continuation of Therapy

Reauthorizations may be approved when **ALL** the following is met:

1. The member remains ambulatory as defined by a current 6MWT of ≥ 200 meters (test must have been observed or completed by the treating provider, or ordered by the treating provider and completed by a qualified medical practitioner)
2. The member has a stable or improving pattern of 6MWTs as shown in medical records with results of a pretreatment baseline and all interim results (all previous 6MWTs results must be included)
3. Dosing remains appropriate
4. The member continues to utilize corticosteroids in combination with the requested agent **OR** demonstrated contraindication to corticosteroids
5. Member has a stable or improving pattern of observed performance on at least TWO of the following five timed function tests as shown in medical records (all results for all tests must be included with the date of performance; tests must have been observed or completed by the treating provider, or ordered by the treating provider and completed by a qualified medical practitioner):
 - a. Timed ten-meter walk/run (time in seconds)
 - b. Timed floor (supine) to stand (time in seconds)
 - c. Timed four-step descend (time in seconds)
 - d. Timed four-step climb (time in seconds)
 - e. Timed sit to stand (time in seconds)

Limitations

1. Initial approvals and reauthorizations will be granted for 3 months.

Appendix

Amenable Exon Deletions: Exon 53 Skipping

- 42-52
- 45-52
- 47-52
- 48-52
- 49-52
- 50-52
- 52
- 54-58

References

1. Vyondys 53 (golodirsen) [prescribing information]. Cambridge, MA: Sarepta Therapeutics Inc; Jun 2024
2. Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. *Neurology* 2020; 94:e2270



3. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. <https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation> (Accessed on December 17, 2019).

Review History

09/16/2020: Created and Reviewed at Sept P&T Meeting. Effective 12/01/2020.

02/08/2023 - Reviewed and updated for Feb P&T. Matched MH UPPL criteria. Vyondys 53 was added to the pharmacy benefit. Updated included: approval durations changed to 3 months, added requirement of baseline measurements, updated neurologist to neuromuscular neurologist, and requirement of appropriate dosing. Effective 4/1/23.

07/12/23 – Reviewed and updated for P&T. Minor language update. No clinical changes. Effective 7/31/23.

05/15/25 – Reviewed and updated for P&T. Updated formatting and references. Effective 6/1/25

